NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $69.41 +1.95 (+2.89 %) (As of 05/21/2019 02:37 PM ET)Previous Close$67.46Today's Range$67.57 - $69.7552-Week Range$40.91 - $86.58Volume20,217 shsAverage Volume1.17 million shsMarket Capitalization$9.74 billionP/E Ratio23.43Dividend YieldN/ABeta2.31 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Receive IONS News and Ratings via Email Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS Previous Symbol CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone760-931-9200Debt Debt-to-Equity Ratio0.47 Current Ratio9.40 Quick Ratio7.85Price-To-Earnings Trailing P/E Ratio23.43 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$599.67 million Price / Sales16.24 Cash Flow$3.2958 per share Price / Cash Flow21.06 Book Value$9.89 per share Price / Book7.02Profitability EPS (Most Recent Fiscal Year)$2.96 Net Income$273.74 million Net Margins47.74% Return on Equity44.03% Return on Assets18.64%Miscellaneous Employees737 Outstanding Shares140,323,000Market Cap$9.74 billion Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its quarterly earnings data on Thursday, May, 9th. The company reported $0.62 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.19. The company earned $297 million during the quarter, compared to analysts' expectations of $285.43 million. Ionis Pharmaceuticals had a return on equity of 44.03% and a net margin of 47.74%. The firm's revenue for the quarter was up 106.3% on a year-over-year basis. During the same period last year, the firm earned ($0.01) EPS. View Ionis Pharmaceuticals' Earnings History. When is Ionis Pharmaceuticals' next earnings date? Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Ionis Pharmaceuticals. What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $725 million, compared to the consensus revenue estimate of $816.4 million. What price target have analysts set for IONS? 8 Wall Street analysts have issued 12 month price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $48.00 to $96.00. On average, they expect Ionis Pharmaceuticals' share price to reach $64.3750 in the next twelve months. This suggests that the stock has a possible downside of 7.3%. View Analyst Price Targets for Ionis Pharmaceuticals. What is the consensus analysts' recommendation for Ionis Pharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals. What are Wall Street analysts saying about Ionis Pharmaceuticals stock? Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock: 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (5/3/2019) 2. Cantor Fitzgerald analysts commented, ". $68 PT. Biogen (BIIB, Young, Neutral) reported earnings this morning and discussed the outlook for Spinraza, which is a key product for Ionis (receives low-20s royalty). Incremental color suggests that the broader SMA market, especially ex-US, is likely much larger than initially expected. However, we see disruptive potential from competitors (risdiplam and gene therapy) which continues to leave us cautious on the long-term Spinraza opportunity. We are hosting a conference call on Monday at 10 AM ET to discuss our thoughts on the key SMA competitor updates expected at AAN (early May) and stock reads to IONS, BIIB and PTCT (Overweight, Young). Call details below." (4/24/2019) Has Ionis Pharmaceuticals been receiving favorable news coverage? News articles about IONS stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a news sentiment score of 1.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of Ionis Pharmaceuticals' key competitors? Some companies that are related to Ionis Pharmaceuticals include Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), BioMarin Pharmaceutical (BMRN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC) and Sarepta Therapeutics (SRPT). What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), BlackRock (BLK), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Celgene (CELG), Endologix (ELGX), Allergan (AGN), Intercept Pharmaceuticals (ICPT) and Micron Technology (MU). Who are Ionis Pharmaceuticals' key executives? Ionis Pharmaceuticals' management team includes the folowing people: Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65) Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.70%), Baillie Gifford & Co. (6.25%), BlackRock Inc. (5.45%), Wellington Management Group LLP (5.37%), First Trust Advisors LP (1.85%) and OppenheimerFunds Inc. (1.45%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals. Which major investors are selling Ionis Pharmaceuticals stock? IONS stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Goldman Sachs Group Inc., Altrinsic Global Advisors LLC, Morgan Stanley, Sector Gamma AS, Wells Fargo & Company MN, Baillie Gifford & Co. and Sicart Associates LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals. Which major investors are buying Ionis Pharmaceuticals stock? IONS stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, First Trust Advisors LP, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Candriam Luxembourg S.C.A., Federated Investors Inc. PA, FMR LLC and Decatur Capital Management Inc.. View Insider Buying and Selling for Ionis Pharmaceuticals. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $69.41. How big of a company is Ionis Pharmaceuticals? Ionis Pharmaceuticals has a market capitalization of $9.74 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe. What is Ionis Pharmaceuticals' official website? The official website for Ionis Pharmaceuticals is http://www.ionispharma.com. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200. MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 523 (Vote Outperform)Underperform Votes: 569 (Vote Underperform)Total Votes: 1,092MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Why is cost of goods sold important? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.